A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R.sub.1 and R.sub.2 are independently C.sub.1-30alkyl (R.sub.3, R.sub.3, R.sub.4, R.sub.5, W and n are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

##STR00001##

A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R.sub.1 and R.sub.2 are independently C.sub.1-30alkyl (R.sub.3, R.sub.3, R.sub.4, R.sub.5, W and n are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

##STR00001##

A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R.sub.1 and R.sub.2 are independently C.sub.1-30alkyl (R.sub.3, R.sub.3, R.sub.4, R.sub.5, W and n are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

##STR00001##

The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory ageiAge, the cardiovascular agecAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.

The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory ageiAge, the cardiovascular agecAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

An anti-cancer agent is provided comprising a tumour homing peptide having, or having been modified to present, two cysteine residues, with an arsenic atom between, such that the tumour homing peptide cyclises to give an arsenic-containing anti-cancer agent. This allows for selection of an appropriate tumour homing peptide for treatment of a given cancer whereby the subsequent agent provides for a more targeted delivery of arsenic to the tumour microenvironment.

An anti-cancer agent is provided comprising a tumour homing peptide having, or having been modified to present, two cysteine residues, with an arsenic atom between, such that the tumour homing peptide cyclises to give an arsenic-containing anti-cancer agent. This allows for selection of an appropriate tumour homing peptide for treatment of a given cancer whereby the subsequent agent provides for a more targeted delivery of arsenic to the tumour microenvironment.